<DOC>
	<DOCNO>NCT01968161</DOCNO>
	<brief_summary>We propose use unique facility , databank CNDV , examine impact switch subject asenapine open-label naturalistic setting . This offer follow advantage : ) provide data particularly important population , i.e. , subject inception treatment psychotic disorder likely remain give drug long-term basis ; ii ) inclusion rich clinical setting , clinical team dedicate provide innovative intervention ; iii ) naturalistic design , allow obtain data applicable `` real-life '' clinical setting ; indeed , subject switch asenapine within current project would switch drug daily practice .</brief_summary>
	<brief_title>Investigator Initiated Study - Asenapine Early Psychosis</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Schizophrenia Spectrum Other Psychotic Disorders</mesh_term>
	<mesh_term>Asenapine</mesh_term>
	<criteria>Meeting DSMIV criterion schizophrenia ( SZ ) relate SZ spectrum psychotic disorder provide consent include data databank , able provide inform consent willingness participate assessment 18 year age clinical situation warrant switch asenapine suffer primary druginduced psychosis significant risk suicide assault unstable medical condition persistence psychotic symptom despite adequate treatment extent clozapine would require treated antipsychotic 5 year contraindication ( allergy asenapine ) pregnant lactate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>